Efficacy of combination chemotherapy with paclitaxel and cisplatin in patients with advanced non-small cell lung cancer
Open accessAbstract
PURPOSE: To evaluate the efficacy and toxicity of the combination therapy of paclitaxel and cisplatin in advanced, non-small cell, lung cancer patients. MATERIALS AND METHODS: Between December 1997 and September 2001, 37 patients with advanced, non-small cell, lung cancer were enrolled in this study. Patients were treated with paclitaxel (135 mg/m2, 24 hr infusion) and cisplatin (75 mg/m2). The treatments were repeated every 4 weeks. RESULTS: Among the 37 patients enrolled, 21 were treated with paclitaxel and cisplatin as a first-line and 16 patients as a second-line. The median age of the patients was 59. In the first-line group, 10 had stage IIIB and 11 had stage IV, non small cell lung cancer. Of 21 patients in first-line treatment group that could be evaluated, objective responses were observed in 6 patients (response rate: 28.6%, CR: 4.8%, PR: 23.8%). The mediansurvival duration for patients was 48 weeks. With the second-line group, 3 patients showed a partial response (response rate: 18.7%) to treatment, with median survival duration of 44 weeks. Grade 3-4 leukopenia was observed in 27.1% of the first-line, and 23.6% in second- line, treatment groups. CONCLUSION: Combination chemotherapy, with paclitaxel and cisplatin, in non-small cell lung cancer has acceptable toxicities in both first and second-line treatment groups. In terms of efficacy, no superior response was shown for either group. More randomized studies, with a larger group of patients, are required to prove the true efficacy.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Sequential PTX followed by a platinum-based regimen is currently first-line therapy for ovarian cancer and a common treatment for breast cancer.
“The combination chemotherapy using sequential administration of paclitaxel (PTX) followed by a platinum-based regimen is currently the first-line therapy for ovarian cancer as well as common treatment for breast cancer [1, 2].”
From Co-delivery of Paclitaxel and Cisplatin in Poly(2-oxazoline) Polymeric Micelles: Implications for Drug Loading, Release, Pharmacokinetics and Outcome of Ovarian and Breast Cancer Treatments (2019) · cites this paper as [2]
The treatment-methods passage (결론 section; page unavailable) describes paclitaxel given before cisplatin, but the patients had advanced non-small-cell lung cancer. The discussion in the same section says paclitaxel is effective against ovarian and breast cancers; it does not say the sequential combination is first-line therapy for ovarian cancer or a common breast-cancer treatment. (LLM, conf=0.85)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Rapp, E., Pater, J. L., Willan, A. R., Cormier, Y. F., Murray, N., Evans, W. K., Hodson, D. I., Clark, D., Feld, R. D., & Arnold, A. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.4.633 · Cited by 695 · see citing works
Microtubules and actin filaments: dynamic targets for cancer chemotherapy
Jordan, M. A., & Wilson, L. (1998) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(98)80095-1 · Cited by 613 · see citing works
Wood, A. J. J., & Ihde, D. C. (1992) · New England Journal of Medicine · doi:10.1056/nejm199211123272006 · Cited by 432 · see citing works
Taxol sensitizes human astrocytoma cells to radiation.
Tishler, R. B., Geard, C. R., Hall, E. J., et al. (1992) · PubMed · Cited by 267 · see citing works
Second-line chemotherapy for recurrent non-small cell lung cancer: do new agents make a difference?
Ferrigno, D., & Buccheri, G. (2000) · Lung Cancer · doi:10.1016/s0169-5002(00)00112-4 · Cited by 38 · see citing works
Phase II study of paclitaxel and cisplatin in patients with non-small cell lung cancer.
von Pawel, J., Wagner, H., Niederle, N., et al. (1996) · PubMed · Cited by 29 · see citing works
Taxanes in lung cancer: a review with focus on the European experience
Calderoni, A., & Cerny, T. (2001) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(00)00121-9 · Cited by 22 · see citing works
Bunn, P. A. (1997) · PubMed · Cited by 22 · see citing works
New treatment agents for advanced small cell and non-small cell lung cancer
Bunn, P. A. (1995) · Lung Cancer · doi:10.1016/0169-5002(96)84339-x · Cited by 13 · see citing works
Changing trends of clinical aspects in lung cancer from 1988 to 1999
Shin, M.-H., Chae, S. C., Kim, C., et al. (2000) · Lung Cancer · doi:10.1016/s0169-5002(00)80801-6 · Cited by 6 · see citing works
Flagged first, then by citations
Research works printed but not linked: 5
- Ginsberg RJ, Vokes EE, Raben A. Cancer of the lung. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Prin- ciples and practice of oncology, 6th edit, Philadelphia: Lippincott-Raven, 2001:925-1017.
- Webb A, O'Brien M. Where to go with new expensive treat- ment in NSCLC. Br J Cancer 1998;78(2):159-162.
- Crino L, Clerici M, Figoli F. Chemotherapy of advanced non- small cell lung cancer: a comparison of three active regimens. Ann Oncol 1995;6:347-353.
- Ginsberg RJ, Vokes EE, Raben A. Principles of cancer man- agement: Chemotherapy. In: DeVita VT Jr, Hellman S, Ro- senberg SA, eds. Cancer: Principles and practice of oncology, 6th edit, Philadelphia: Lippincott-Raven, 2001:437-445.
- Bonomi P, Kim K, Fairclough D, et al. Comparison of survival and quality of life in advanced non-small cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of and Eastern Cooperative Oncology Group trial. J Clin Oncol 2000; 18(3):623-631.
Cited by
Sorted by citations
Wan, X., Beaudoin, J. J., Vinod, N., Min, Y., Makita, N., Bludau, H., Jordan, R., Wang, A., Sokolsky, M., & Kabanov, A. V. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2018.10.032 · Cited by 201 · see citing works
“The combination chemotherapy using sequential administration of paclitaxel (PTX) followed by a platinum-based regimen is currently the first-line therapy for ovarian cancer as well as common treatment for breast cancer [1, 2].”
Background
- Authors
- Rhee, E. J., Jeong, H. S., & Lee, S. S.
- Affiliations
- Kangbuk Samsung Hospital (KR)
- Venue
- Cancer Research and Treatment
- Publisher
- Korean Cancer Association
- Published
- 2002-02-28
- Volume
- 34
- Issue
- 1
- Pages
- 28-33
- ISSN
- 1598-2998 (ISSN-L)
- 2005-9256
- OpenAlex
- W2282516002
- Cited by
- 4
- References
- 10
- Citations by year
- 2026: 1 · 2018: 1
- FWCI
- 0.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer Research and Treatment (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- paclitaxel, cisplatin, combination chemotherapy, non-small cell lung cancer, advanced lung cancer, first-line therapy, second-line therapy, objective response rate, survival, leukopenia, chemotherapy toxicity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
